FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126419005> ?p ?o ?g. }

• W3126419005 endingPage "1390" @default.
• W3126419005 startingPage "1377" @default.
• W3126419005 abstract "In patients with heart failure and atrial fibrillation (AF), several clinical trials have reported improved outcomes, including freedom from AF recurrence, quality of life, and survival, with catheter ablation. This article describes the treatment-related outcomes of the AF patients with heart failure enrolled in the CABANA trial (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation).The CABANA trial randomized 2204 patients with AF who were ≥65 years old or <65 years old with ≥1 risk factor for stroke at 126 sites to ablation with pulmonary vein isolation or drug therapy including rate or rhythm control drugs. Of these, 778 (35%) had New York Heart Association class >II at baseline and form the subject of this article. The CABANA trial's primary end point was a composite of death, disabling stroke, serious bleeding, or cardiac arrest.Of the 778 patients with heart failure enrolled in CABANA, 378 were assigned to ablation and 400 to drug therapy. Ejection fraction at baseline was available for 571 patients (73.0%), and 9.3% of these had an ejection fraction <40%, whereas 11.7% had ejection fractions between 40% and 50%. In the intention-to-treat analysis, the ablation arm had a 36% relative reduction in the primary composite end point (hazard ratio, 0.64 [95% CI, 0.41-0.99]) and a 43% relative reduction in all-cause mortality (hazard ratio, 0.57 [95% CI, 0.33-0.96]) compared with drug therapy alone over a median follow-up of 48.5 months. AF recurrence was decreased with ablation (hazard ratio, 0.56 [95% CI, 0.42-0.74]). The adjusted mean difference for the AFEQT (Atrial Fibrillation Effect on Quality of Life) summary score averaged over the entire 60-month follow-up was 5.0 points, favoring the ablation arm (95% CI, 2.5-7.4 points), and the MAFSI (Mayo Atrial Fibrillation-Specific Symptom Inventory) frequency score difference was -2.0 points, favoring ablation (95% CI, -2.9 to -1.2).In patients with AF enrolled in the CABANA trial who had clinically diagnosed stable heart failure at trial entry, catheter ablation produced clinically important improvements in survival, freedom from AF recurrence, and quality of life relative to drug therapy. These results, obtained in a cohort most of whom had preserved left ventricular function, require independent trial verification. Registration: URL: https://www.clinicaltrials.gov/ct2/show/NCT00911508; Unique identifier: NCT0091150." @default.
• W3126419005 created "2021-02-15" @default.
• W3126419005 creator A5023346746 @default.
• W3126419005 creator A5034517651 @default.
• W3126419005 creator A5043658621 @default.
• W3126419005 creator A5055158512 @default.
• W3126419005 creator A5070387023 @default.
• W3126419005 creator A5080215907 @default.
• W3126419005 creator A5080697161 @default.
• W3126419005 creator A5087516645 @default.
• W3126419005 creator A5090658395 @default.
• W3126419005 creator A5090762512 @default.
• W3126419005 date "2021-04-06" @default.
• W3126419005 modified "2023-10-06" @default.
• W3126419005 title "Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure" @default.
• W3126419005 cites W1963810099 @default.
• W3126419005 cites W1971423330 @default.
• W3126419005 cites W1971505725 @default.
• W3126419005 cites W1984289573 @default.
• W3126419005 cites W198854710 @default.
• W3126419005 cites W2020346401 @default.
• W3126419005 cites W2023143117 @default.
• W3126419005 cites W2025008619 @default.
• W3126419005 cites W2026044573 @default.
• W3126419005 cites W2038981426 @default.
• W3126419005 cites W2111786081 @default.
• W3126419005 cites W2115347173 @default.
• W3126419005 cites W2145391133 @default.
• W3126419005 cites W2148910374 @default.
• W3126419005 cites W2151074096 @default.
• W3126419005 cites W2157362354 @default.
• W3126419005 cites W2159999579 @default.
• W3126419005 cites W2161117732 @default.
• W3126419005 cites W2333399234 @default.
• W3126419005 cites W2464054063 @default.
• W3126419005 cites W2475261460 @default.
• W3126419005 cites W2529952147 @default.
• W3126419005 cites W2537707689 @default.
• W3126419005 cites W2546977322 @default.
• W3126419005 cites W2612100421 @default.
• W3126419005 cites W2747726107 @default.
• W3126419005 cites W2775066728 @default.
• W3126419005 cites W2786615201 @default.
• W3126419005 cites W2786781710 @default.
• W3126419005 cites W2790162467 @default.
• W3126419005 cites W2888065771 @default.
• W3126419005 cites W2912772408 @default.
• W3126419005 cites W2913815352 @default.
• W3126419005 cites W2920804236 @default.
• W3126419005 cites W2920839885 @default.
• W3126419005 cites W2921787764 @default.
• W3126419005 cites W2945334580 @default.
• W3126419005 cites W2945392393 @default.
• W3126419005 cites W2954348337 @default.
• W3126419005 cites W2991235505 @default.
• W3126419005 cites W3006483564 @default.
• W3126419005 cites W3030533492 @default.
• W3126419005 cites W3036182639 @default.
• W3126419005 cites W4230645380 @default.
• W3126419005 cites W4293241248 @default.
• W3126419005 cites W59237391 @default.
• W3126419005 doi "https://doi.org/10.1161/circulationaha.120.050991" @default.
• W3126419005 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8030730" @default.
• W3126419005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33554614" @default.
• W3126419005 hasPublicationYear "2021" @default.
• W3126419005 type Work @default.
• W3126419005 sameAs 3126419005 @default.
• W3126419005 citedByCount "192" @default.
• W3126419005 countsByYear W31264190052021 @default.
• W3126419005 countsByYear W31264190052022 @default.
• W3126419005 countsByYear W31264190052023 @default.
• W3126419005 crossrefType "journal-article" @default.
• W3126419005 hasAuthorship W3126419005A5023346746 @default.
• W3126419005 hasAuthorship W3126419005A5034517651 @default.
• W3126419005 hasAuthorship W3126419005A5043658621 @default.
• W3126419005 hasAuthorship W3126419005A5055158512 @default.
• W3126419005 hasAuthorship W3126419005A5070387023 @default.
• W3126419005 hasAuthorship W3126419005A5080215907 @default.
• W3126419005 hasAuthorship W3126419005A5080697161 @default.
• W3126419005 hasAuthorship W3126419005A5087516645 @default.
• W3126419005 hasAuthorship W3126419005A5090658395 @default.
• W3126419005 hasAuthorship W3126419005A5090762512 @default.
• W3126419005 hasBestOaLocation W31264190051 @default.
• W3126419005 hasConcept C126322002 @default.
• W3126419005 hasConcept C127413603 @default.
• W3126419005 hasConcept C141071460 @default.
• W3126419005 hasConcept C164705383 @default.
• W3126419005 hasConcept C168563851 @default.
• W3126419005 hasConcept C203092338 @default.
• W3126419005 hasConcept C207103383 @default.
• W3126419005 hasConcept C2776131983 @default.
• W3126419005 hasConcept C2778198053 @default.
• W3126419005 hasConcept C2779161974 @default.
• W3126419005 hasConcept C2780645631 @default.
• W3126419005 hasConcept C44249647 @default.
• W3126419005 hasConcept C71924100 @default.
• W3126419005 hasConcept C78085059 @default.
• W3126419005 hasConcept C78519656 @default.

• next